News

The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of ...
2 Researchers in the U.K. recently reviewed published studies on wet AMD and examined 231 individual cases from an extended cohort. The 7 studies included in the analysis, which offered mixed ...
“This BLA acceptance and PDUFA date are significant milestones in our continued mission to offer clinicians and their patients the first and only on-label, ophthalmic bevacizumab to treat wet ...
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire wet age-related macular degeneration (AMD) program. Sozinibercept ...
The trials for Wet AMD were a central part of Opthea’s research and development efforts. InvestingPro analysis indicates the company’s overall financial health score is currently weak ...
Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD ...
Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention- Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs ...
“As the leader in suprachoroidal delivery, we valued the opportunity to participate in this industry dialogue on recent advancements and emerging therapies to improve treatment options for wet ...
Also Read: Analyst Sees Wendy’s Playing Catch-Up, Needs Stronger Focus on Tech, Talent & Global Expansion Ocular Therapeutix has completed randomization in the first wet AMD trial, SOL-1.
Wet AMD remains the leading cause of vision loss in the elderly, impacting about 3.5 million people in the US and Europe alone. The unmet medical need in wet AMD is significant, with many ...
Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population. In so-called wet AMD, new, abnormal blood vessels grow in the central part ...